Literature DB >> 20157236

Antisaccades: a probe into the dorsolateral prefrontal cortex in Alzheimer's disease. A critical review.

Liam D Kaufman1, Jay Pratt, Brian Levine, Sandra E Black.   

Abstract

The number of people living with Alzheimer's disease (AD), the major cause of dementia, is projected to increase dramatically over the next few decades, making the search for treatments and tools to measure the progression of AD increasingly urgent. The antisaccade task, a hands- and language-free measure of inhibitory control, has been utilized in AD as a potential diagnostic test. While antisaccades do not appear to differentiate AD from healthy aging better than measures of episodic memory, they may still be beneficial. Specifically, antisaccades may provide not only a functional index of the Dorsolateral Prefrontal Cortex (DLPFC), which is damaged in the later stages of AD, but also a tool for monitoring the progression of AD. Further work is required to: 1) strengthen the link between antisaccade errors, in AD, with the DLPFC; 2) insure that antisaccade errors do not result from memory, visuospatial, or other deficits associated with AD; and 3) further validate the clinical analogue of the antisaccade task.

Entities:  

Mesh:

Year:  2010        PMID: 20157236     DOI: 10.3233/JAD-2010-1275

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  27 in total

1.  Novel methods for integration and visualization of genomics and genetics data in Alzheimer's disease.

Authors:  Nathan A Bihlmeyer; Emily Merrill; Yann Lambert; Gyan P Srivastava; Timothy W Clark; Bradley T Hyman; Sudeshna Das
Journal:  Alzheimers Dement       Date:  2019-03-29       Impact factor: 21.566

2.  Distinctive features of microsaccades in Alzheimer's disease and in mild cognitive impairment.

Authors:  Zoi Kapoula; Qing Yang; Jorge Otero-Millan; Shifu Xiao; Stephen L Macknik; Alexandre Lang; Marc Verny; Susana Martinez-Conde
Journal:  Age (Dordr)       Date:  2013-09-15

3.  Effects of nicotine on response inhibition and interference control.

Authors:  Ulrich Ettinger; Eliana Faiola; Anna-Maria Kasparbauer; Nadine Petrovsky; Raymond C K Chan; Roman Liepelt; Veena Kumari
Journal:  Psychopharmacology (Berl)       Date:  2017-02-01       Impact factor: 4.530

4.  VisualEyes: a modular software system for oculomotor experimentation.

Authors:  Yi Guo; Eun H Kim; Eun Kim; Tara Alvarez; Tara L Alvarez
Journal:  J Vis Exp       Date:  2011-03-25       Impact factor: 1.355

5.  Pharmacological Manipulation of Cortical Inhibition in the Dorsolateral Prefrontal Cortex.

Authors:  Bahar Salavati; Tarek K Rajji; Reza Zomorrodi; Daniel M Blumberger; Robert Chen; Bruce G Pollock; Zafiris J Daskalakis
Journal:  Neuropsychopharmacology       Date:  2017-05-29       Impact factor: 7.853

Review 6.  Eye movements in Alzheimer's disease.

Authors:  Robert J Molitor; Philip C Ko; Brandon A Ally
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

7.  Imaging the Alzheimer brain.

Authors:  J Wesson Ashford; Ahmad Salehi; Ansgar Furst; Peter Bayley; Giovanni B Frisoni; Clifford R Jack; Osama Sabri; Maheen M Adamson; Kerry L Coburn; John Olichney; Norbert Schuff; Daniel Spielman; Steven D Edland; Sandra Black; Allyson Rosen; David Kennedy; Michael Weiner; George Perry
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 8.  Ocular motor abnormalities in neurodegenerative disorders.

Authors:  C A Antoniades; C Kennard
Journal:  Eye (Lond)       Date:  2014-11-21       Impact factor: 3.775

9.  The role of working memory and attentional disengagement on inhibitory control: effects of aging and Alzheimer's disease.

Authors:  Trevor J Crawford; Steve Higham; Jenny Mayes; Mark Dale; Sandip Shaunak; Godwin Lekwuwa
Journal:  Age (Dordr)       Date:  2012-08-18

Review 10.  Prosaccade and Antisaccade Paradigms in Persons with Alzheimer's Disease: A Meta-Analytic Review.

Authors:  Naomi Kahana Levy; Michal Lavidor; Eli Vakil
Journal:  Neuropsychol Rev       Date:  2017-10-27       Impact factor: 7.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.